{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000057","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.268206+00:00","generated_at":"2026-06-06T01:20:26.451100+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Zentalis adopts amended bylaws with universal proxy rule compliance","bullets":["Board approved Amended and Restated Bylaws effective February 12, 2024.","Amendments address SEC universal proxy rules under Rule 14a-19, including notice and solicitation requirements.","Enhanced disclosure requirements for stockholder director nominations and other business proposals.","Prohibits proposing more nominees than directors up for election.","Includes technical, modernizing, clarifying, and conforming changes."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000057","json":"https://secwatch.observer/filing/0001725160-24-000057.json","markdown":"https://secwatch.observer/filing/0001725160-24-000057.md","text":"https://secwatch.observer/filing/0001725160-24-000057.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000057/0001725160-24-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000057/zntl-20240212.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T01:20:26.451100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a59f65970e25ef59c731866b6ae39f499b7f0146","claim":"Zentalis Pharmaceuticals, Inc.: Amended and Restated Bylaws to address universal proxy rules, streamline stockholder nomination procedures, and prohibit excessive director nominees; effective February 12, 2024 (effective 2024-02-12).","evidence_excerpt":"On February 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) approved and adopted amendments to the Company’s Bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000057/0001725160-24-000057-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2024-02-12"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}